Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Time to progression · people with advanced gastric cancer
Chemotherapy probably leads to lower time to progression compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects · people with metastatic CRC
Chemotherapy probably leads to higher severe adverse effects compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table (subcomparison 1): chemotherapy or… leads to lower overall survival compared with BSC (high certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table (subcomparison 1): chemotherapy or… changes progression‐free survival compared with BSC (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table (subcomparison 1): chemotherapy or… changes toxicity compared with BSC (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with esophageal and GE‐junction carcinoma
1 finding from 1 review
Overall survival · patients with extensive SCLC without previous treatment
1 finding from 1 review
Adverse effects · patients with extensive SCLC without previous treatment
1 finding from 1 review